Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 419

1.

Association of dietary factors with severity of coronary artery disease.

Mahalle N, Garg MK, Naik SS, Kulkarni MV.

Clin Nutr ESPEN. 2016 Oct;15:75-79. doi: 10.1016/j.clnesp.2016.06.004. Epub 2016 Jun 29.

PMID:
28531788
2.

2017 Taiwan lipid guidelines for high risk patients.

Li YH, Ueng KC, Jeng JS, Charng MJ, Lin TH, Chien KL, Wang CY, Chao TH, Liu PY, Su CH, Chien SC, Liou CW, Tang SC, Lee CC, Yu TY, Chen JW, Wu CC, Yeh HI; Writing Group of 2017 Taiwan Lipid Guidelines for High Risk Patients.

J Formos Med Assoc. 2017 Apr;116(4):217-248. doi: 10.1016/j.jfma.2016.11.013. Epub 2017 Feb 24. Review.

3.

Effect of Combination Cholesterol-Lowering Therapy and Triglyceride-Lowering Therapy on Medical Costs in Patients With Type 2 Diabetes Mellitus.

Nichols GA, Reynolds K, Olufade T, Kimes TM, O'Keeffe-Rosetti M, Sapp DS, Anzalone D, Fortmann SP.

Am J Cardiol. 2017 Feb 1;119(3):410-415. doi: 10.1016/j.amjcard.2016.10.029. Epub 2016 Nov 4.

PMID:
27890243
4.

Glycaemic Effects of Non-statin Lipid-Lowering Therapies.

Collins PD, Sattar N.

Curr Cardiol Rep. 2016 Dec;18(12):133. Review.

5.

Effect of selected clinical trial publication on adjunctive nonstatin medication prescribing in the Veterans Health Administration system.

Titus-Rains KS, Cantrell MA, Egge JA, Alexander B, Shaw RF, Argo TR.

Am J Health Syst Pharm. 2016 Dec 1;73(23 Supplement 6):S141-S147.

PMID:
27864237
6.

Concentrations of Water-Soluble Vitamins in Blood and Urinary Excretion in Patients with Diabetes Mellitus.

Iwakawa H, Nakamura Y, Fukui T, Fukuwatari T, Ugi S, Maegawa H, Doi Y, Shibata K.

Nutr Metab Insights. 2016 Nov 1;9:85-92. eCollection 2016.

7.

Hypertriglyceridemia: the importance of identifying patients at risk.

Kushner PA, Cobble ME.

Postgrad Med. 2016 Nov;128(8):848-858. Epub 2016 Oct 12. Review.

PMID:
27710158
8.

Nutrient patterns and their relationship to metabolic syndrome in Iranian adults.

Khayyatzadeh SS, Moohebati M, Mazidi M, Avan A, Tayefi M, Parizadeh SM, Ebrahimi M, Heidari-Bakavoli A, Azarpazhooh MR, Esmaily H, Ferns GA, Nematy M, Safarian M, Ghayour-Mobarhan M.

Eur J Clin Invest. 2016 Oct;46(10):840-52. doi: 10.1111/eci.12666.

PMID:
27529331
9.

Managing dyslipidaemia in type 2 diabetes mellitus.

Szalat A, Durst R, Leitersdorf E.

Best Pract Res Clin Endocrinol Metab. 2016 Jun;30(3):431-44. doi: 10.1016/j.beem.2016.05.004. Epub 2016 May 28. Review.

PMID:
27432076
10.

Effects of extended-release niacin/laropiprant on correlations between apolipoprotein B, LDL-cholesterol and non-HDL-cholesterol in patients with type 2 diabetes.

Brinton EA, Triscari J, Brudi P, Chen E, Johnson-Levonas AO, Sisk CM, Ruck RA, MacLean AA, Maccubbin D, Mitchel YB.

Lipids Health Dis. 2016 Jul 12;15(1):116. doi: 10.1186/s12944-016-0282-8.

11.

[Residual risk: The roles of triglycerides and high density lipoproteins].

Grammer T, Kleber M, Silbernagel G, Scharnagl H, März W.

Dtsch Med Wochenschr. 2016 Jun;141(12):870-7. doi: 10.1055/s-0042-104049. Epub 2016 Jun 15. German.

PMID:
27305303
12.

Effects of an Antimutagenic 1,4-Dihydropyridine AV-153 on Expression of Nitric Oxide Synthases and DNA Repair-related Enzymes and Genes in Kidneys of Rats with a Streptozotocin Model of Diabetes Mellitus.

Ošiņa K, Rostoka E, Isajevs S, Sokolovska J, Sjakste T, Sjakste N.

Basic Clin Pharmacol Toxicol. 2016 Nov;119(5):458-463. doi: 10.1111/bcpt.12617. Epub 2016 May 30.

PMID:
27163882
13.

Effects of Extended-Release Niacin Added to Simvastatin/Ezetimibe on Glucose and Insulin Values in AIM-HIGH.

Goldberg RB, Bittner VA, Dunbar RL, Fleg JL, Grunberger G, Guyton JR, Leiter LA, McBride R, Robinson JG, Simmons DL, Wysham C, Xu P, Boden WE.

Am J Med. 2016 Jul;129(7):753.e13-22. doi: 10.1016/j.amjmed.2016.02.039. Epub 2016 Mar 29.

14.

A Therapeutic Insight of Niacin and Coenzyme Q10 Against Diabetic Encephalopathy in Rats.

Motawi TK, Darwish HA, Hamed MA, El-Rigal NS, Naser AFA.

Mol Neurobiol. 2017 Apr;54(3):1601-1611. doi: 10.1007/s12035-016-9765-x. Epub 2016 Feb 11. Erratum in: Mol Neurobiol. 2017 Mar 20;:. Mol Neurobiol. 2017 Jul;54(5):3924.

PMID:
26867655
15.

Lipoprotein hydrophobic core lipids are partially extruded to surface in smaller HDL: "Herniated" HDL, a common feature in diabetes.

Amigó N, Mallol R, Heras M, Martínez-Hervás S, Blanco Vaca F, Escolà-Gil JC, Plana N, Yanes Ó, Masana L, Correig X.

Sci Rep. 2016 Jan 18;6:19249. doi: 10.1038/srep19249.

16.

Anti-inflammatory effects of the hydroxycarboxylic acid receptor 2.

Graff EC, Fang H, Wanders D, Judd RL.

Metabolism. 2016 Feb;65(2):102-13. doi: 10.1016/j.metabol.2015.10.001. Epub 2015 Nov 13. Review.

PMID:
26773933
17.

Niacin: old habits die hard.

Haynes R, Rahimi K.

Heart. 2016 Feb;102(3):170-1. doi: 10.1136/heartjnl-2015-308558. No abstract available.

PMID:
26769376
18.

Potential Drug Combinations to Reduce Cardiovascular Disease Burden in Diabetes.

Pillarisetti S.

Trends Pharmacol Sci. 2016 Mar;37(3):207-19. doi: 10.1016/j.tips.2015.11.009. Epub 2015 Dec 21. Review.

PMID:
26719218
19.

Effect of niacin on triglyceride-rich lipoprotein apolipoprotein B-48 kinetics in statin-treated patients with type 2 diabetes.

Pang J, Chan DC, Hamilton SJ, Tenneti VS, Watts GF, Barrett PH.

Diabetes Obes Metab. 2016 Apr;18(4):384-91. doi: 10.1111/dom.12622. Epub 2016 Jan 28.

PMID:
26679079
20.

Risk Assessment and Guidelines for the Management of High Triglycerides.

Tannock L, Bhat A.

In: De Groot LJ, Chrousos G, Dungan K, Feingold KR, Grossman A, Hershman JM, Koch C, Korbonits M, McLachlan R, New M, Purnell J, Rebar R, Singer F, Vinik A, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-.
2015 Jul 27.

Supplemental Content

Loading ...
Support Center